Probiotic oral immunotherapy for egg and milk allergy induces sustained unresponsiveness
Pediatric Allergy and Immunology · 2025
DOI: 10.1111/pai.70222 ↗Kurz gefasst
Kontrollierte klinische Studie in der Zeitschrift Pediatric Allergy and Immunology, 2025. Verfasst von Melanie Lloyd und 11 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Immunology, Murdoch Children's Research Institute, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Egg Hypersensitivity, Milk Hypersensitivity, Probiotics. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Prota Therapeutics, Murdoch Children's Research Institute.
Abstract (Originalsprache)
Background
High‐dose rapid‐escalation oral immunotherapy (OIT) with adjunct probiotic is effective at inducing sustained unresponsiveness (SU) of peanut allergy, but the efficacy of this approach for other food allergies is untested. This open‐label study aimed to confirm the safety and tolerability of high‐dose egg and milk oral immunotherapy (OIT) with probiotic in children.
Methods
Participants aged 5–17 years with egg ( n = 20) or milk ( n = 20) allergy confirmed by double‐blind placebo‐controlled food challenge (DBPCFC) received probiotic and either egg or milk OIT for 18 months. SU was assessed by DBPCFC performed post‐treatment (after 8 weeks dietary allergen exclusion). The primary outcome was the proportion completing the dose‐escalation phase according to protocol. Secondary outcomes were the proportion with SU, adverse events (AE), and change in health‐related quality of life (HRQL).
Results
Nine (45%) egg and 7 (35%) milk participants completed the dose‐escalation according to protocol, and 17 (85%) in both groups were able to reach the maintenance phase with dose modifications. Eleven (55%) egg and 10 (50%) milk participants attained SU. Treatment‐related AEs were frequent, with 9 (45%) egg and 13 (65%) milk participants reporting at least one moderate or severe event. Clinically significant improvements in HRQL were observed in both groups.
Conclusion
High‐dose rapid‐escalation OIT with adjunct probiotic is a promising treatment for egg and milk allergy, which may increase the likelihood of achieving SU and shorten the required treatment period for participants. The efficacy and safety of this approach should be confirmed in later‐stage placebo‐controlled randomized trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Immunology, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
- Centre for Medicine Use and Safety, Monash University, Melbourne, Victoria, Australia.
- Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.
- Monash Children's Hospital, Melbourne, Victoria, Australia.
- Rural Allergy Group, Ballarat, Victoria, Australia.
- Royal Children's Hospital, Melbourne, Victoria, Australia.
ORCID-Profile: Melanie Lloyd, Paxton Loke, Sarah Ashley, Hugh Brown
Förderung
- Prota Therapeutics
- Murdoch Children's Research Institute
Zitieren
APA
Lloyd, M., Loke, P., Nguyen, K., Pitkin, S., Ashley, S., Cantlay, A., Burns, J., Brown, H., Orsini, F., Tang, M. L. K., Lozinsky, A. C., & PREMO Study team (2025). Probiotic oral immunotherapy for egg and milk allergy induces sustained unresponsiveness. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.70222
Vancouver
Lloyd M, Loke P, Nguyen K, Pitkin S, Ashley S, Cantlay A, et al. Probiotic oral immunotherapy for egg and milk allergy induces sustained unresponsiveness. Pediatric Allergy and Immunology. 2025. doi:10.1111/pai.70222
BibTeX
@article{Lloyd2025,
author = {Lloyd, Melanie and Loke, Paxton and Nguyen, Kathy and Pitkin, Sigrid and Ashley, Sarah and Cantlay, Andy and Burns, Julie and Brown, Hugh and Orsini, Francesca and Tang, Mimi L K and Lozinsky, Adriana Chebar and PREMO Study team, PREMO Study team},
title = {Probiotic oral immunotherapy for egg and milk allergy induces sustained unresponsiveness},
journal = {Pediatric Allergy and Immunology},
year = {2025},
doi = {10.1111/pai.70222}
}
EUVIMED